|Dr. Matthew C. Coffey||Pres, CEO & Director||568.07k||N/A||N/A|
|Mr. Kirk J. Look CA||Chief Financial Officer||459.96k||N/A||N/A|
|Dr. Andres A. Gutierrez M.D., Ph.D.||Chief Medical Officer||75.04k||N/A||1961|
|Mr. Michael Moore||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Andrew R. de Guttadauro||Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc||N/A||N/A||1967|
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.